(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote In favor of Your Favored Treat - 2Iranian-backed militias escalate in Iraq, targeting Kurdistan Region president Nechirvan Barzani
- 3Alix Earle built trust by sharing her acne woes. Now her skin care line is raising questions.
- 4Our favorite Space.com stories of 2025
- 5Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy
- Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- Posts falsely claim Malaysian minister to relocate public hospital for temple
- Exploring the Gig Economy: Illustrations from Consultants
- These four astronauts could soon travel farther from Earth than anyone has gone before
- Born under fire: MDA delivers baby in Jerusalem minutes before rushing to shelter
- Skeleton of famed musketeer possibly found in Dutch church
- Woman, 60, Is Finally Traveling the World Decades After Husband’s Death Held Her Back
- Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
- Must-See Attractions in Australia
